Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Axonics ModulationTechnologies Inc

Haemonetics

PROCEPT BioRobotics Corp

Shockwave Medical

Biotech isn't the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.

Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year

Transmedics Group Inc

Here we discuss three Medical-Instruments stocks - TMDX, PRCT & SRTS - that continued to grow in the first nine months of 2022 even though three Fed rate hikes dragged broader indices down.

3 Resilient Medical Stocks to Watch as Rate Hikes Continue

BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.  The hybrid format includes in-person meetings in New York City and will be holding one-on-one meetings.  A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time on the investors section of Sensus Healthcare's website or at this link .

Sensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Axonics is breaking out from a three-weeks-tight pattern after announcing it has begin treating patients in Canada. The post Medical Device Maker Announces New Patients, Shoots Past Buy Point appeared first on Investor's Business Daily.

Medical Device Maker Announces New Patients, Shoots Past Buy Point

Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin Includes a new ergonomic probe to operate in ideal MHz range to view all layers of skin

Sensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities

Arcosa Inc

Celsius Holdings

Super Micro Computer

Universal Logistics Hlds

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SRTS, SMCI, ULH, ACA and CELH.

5 Stocks With Recent Price Strength to Enrich Your Portfolio

Sensus Healthcare announced strong Q2 FY2022 results with significant revenue and profit margin growth. The company is experiencing industrial tailwinds as skin cancer patients are continuously increasing globally.

Sensus Healthcare: Best In The Industry With Significant Growth Prospects

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kim Golodetz - Senior Vice President and Principal, Lippert/Heilshorn & Associates Inc. Joe Sardano - Chairman & Chief Executive Officer Javier Rampolla - Chief Financial Officer Conference Call Participants Scott Henry - ROTH Capital Anthony Vendetti - Maxim Group Operator Good day ladies and gentlemen and welcome to the Sensus Healthcare Second Quarter 2022 Earnings Conference Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Kim Golodetz.

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q2 2022 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 16.67% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Q2 Earnings and Revenues Top Estimates

Centennial Resource Development

Columbia Banking System

Crocs

Gambling.com Group

Sachem Capital

iStar Inc

Canada's national business paper, The Globe and Mail, recently interviewed a Toronto-based portfolio manager who seeks out smaller growth stocks with the potential to become large caps over the long haul. Alex Etsell invests $2.3 billion for Hillsdale Investment Management in microcap and small-cap strategies for the firm's clients.

7 Growth Stocks to Buy Now Before They Become Large Caps

BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC), a rapidly-growing chain of Texas-based hair loss treatment centers. The Systems will be used to non-invasively deliver U.SK Under Skin's hair-health serum Skin Savers Hair™.  U.SK Under Skin is a subsidiary of privately-held EMS Pharma, the largest pharmaceutical company in Brazil and itself a subsidiary of Grupo NC, one of Brazil's largest conglomerates.

Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin's Hair-Health Serum

BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) --   Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 4, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022

Sensus Healthcare, Inc. (SRTS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Sensus Healthcare, Inc. (SRTS) Is a Great Choice for "Trend" Investors, Here's Why

Sensus Healthcare, Inc. (SRTS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sensus Healthcare, Inc. (SRTS) Soars 8.7%: Is Further Upside Left in the Stock?

Investors need to pay close attention to Sensus Healthcare (SRTS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Sensus Healthcare (SRTS) Stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 54.6% in Sensus Healthcare, Inc. (SRTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Sensus Healthcare, Inc. (SRTS) Could Rally 55%: Here's is How to Trade

BOCA RATON, Fla, May 23, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022.

Correction: Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference

Sensus Healthcare, Inc. (SRTS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Sensus Healthcare, Inc. (SRTS) Might be Well Poised for a Surge

Sensus has developed an FDA-cleared laser device that targets non-melanoma skin cancers and keloids. While 2021 was a tough time for the company as elective procedures non-existent during the pandemic.

Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month

The consensus price target hints at a 52.9% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Sensus Healthcare, Inc. (SRTS) Could Surge 53%: Read This Before Placing a Bet

BOCA RATON, Fla, May 18, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be participating in the H.C. Wainwright Global Investment Conference taking place virtually and in-person at the Fontainebleau Miami Beach May 23-26, 2022.

Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Kim Golodetz - Senior Vice President and Principal, Lippert/Heilshorn & Associates Inc. Joe Sardano - Chairman & Chief Executive Officer Javier Rampolla - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Sensus Healthcare 1Q 2022 Financial Results Conference Call. All lines have been placed on a listen-only mode and the floor will be open for your questions and comments following the presentation.

Sensus Healthcare, Inc. (SRTS) CEO Joe Sardano on Q1 2022 Results - Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 233.33% and 65.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Beats Q1 Earnings and Revenue Estimates

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sensus Healthcare, Inc. (SRTS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why "Trend" Investors Would Love Betting on Sensus Healthcare, Inc. (SRTS)

Sensus Healthcare, Inc. (SRTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

News for Sensus Healthcare Stock (SRTS)